

Moderna Rep: Everyone Taking COVID-19 Vaccine Is “Pretty Much” Part of a Clinical Trial

By [Mary Villareal](#)

Global Research, August 02, 2021

[BigPharmaNews.com](#) 30 July 2021

Region: [USA](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at [@crg_globalresearch](#).

The leaked audio of a phone call between a Moderna representative and a woman who developed Guillain-Barre syndrome after receiving the company’s experimental drug has confirmed something many of us already knew: We are witnessing the biggest clinical trial in vaccine history.

During the course of conversation, the Moderna representative admitted that all coronavirus (COVID-19) vaccine recipients are “pretty much” part of a drug trial. The audio was released in June by reporter Stew Peters.

Whether the mainstream media admit it or not, COVID-19 vaccines are experimental. No less than the *Food and Drug Administration* (FDA) said so. *Natural Health 365* reported that in a “Guidance for Industry” dated May 25, 2021, the FDA and *Department of Health and Human Services* (HHS) specifically [referred to COVID-19 vaccines](#) as “investigational.”

Investigational vs. experimental drugs, according to FDA

Those who wonder how different “investigational” is from “experimental,” the FDA explained in their web page that “An investigational drug can also be called an experimental drug.”

It also said: “Before you can be given an investigational drug either through a clinical trial or through expanded access, your healthcare provider must give you additional information about the potential risks and potential benefits of the drug.”

Pfizer, Moderna and Johnson & Johnson are not liable for any loss or damages caused by these experimental drugs as stated in the Public Readiness and Emergency Preparedness Act (PREP Act).

The secretary of the *Department of Health and Human Services* (HHS) is authorized to issue a PREP Act declaration. [The declaration provides immunity from liability](#) (except for willful misconduct) for claims of loss caused, arising out of, relating to or resulting from

administration or use of countermeasures to diseases, threats and conditions; for claims determined by the secretary to constitute a present or credible risk of a future public health emergency; and for claims to entities and individuals involved in the development, manufacture, testing, distribution, administration and use of such countermeasures.

This means that if a person gets ill, injured or killed from a COVID-19 vaccine, the pharmaceutical companies will not be held liable. (Related: [Oxford-AstraZeneca's COVID-19 vaccine experiment is tied to eugenics-linked institutions.](#))

Pharmaceutical companies to expand size of trial for younger children

The *Rockdale Newton Citizen* recently reported that [Moderna will expand](#) the size of its vaccine trial in younger children but will not seek emergency use authorization for the age group until later in 2021 or early 2022.

“We are actively discussing a proposal with the FDA. The objective is to enroll a larger safety database which increases the likelihood of detecting rarer events,” Ray Johnson, a spokesperson for Moderna, said in a statement.

The original size of the trial included almost 7,000 children ages 6 months to 12 years. However, the company did not say how many additional cases the trial will now include.

Jordan also said that Moderna would likely seek authorization for the vaccine in “winter 2021” or early 2022.

Pfizer will expand its vaccine trials for younger children, as well. A Pfizer representative said it has no updates regarding its previous timelines or details about its pediatric trial. However, the company noted that it began testing its vaccine in children ages five to 11 on June 8, and on children younger than 5 beginning June 21. The trial now included up to 4,500 participants in the United States, Finland, Poland and Spain.

Pfizer also said it expects initial results of the second phase of the trials in September for children ages 5 to 11, and the younger ones shortly thereafter.

President Joe Biden said that children under 12 could be eligible to receive their COVID-19 vaccine “soon.” Parents have been eager to vaccinate their younger children as schools prepare to open face-to-face learning in the fall. The Pfizer vaccine is currently available for children as young as 12, but no vaccine is available for younger children yet.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from BigPharmaNews.com

The original source of this article is [BigPharmaNews.com](#)

Copyright © [Mary Villareal](#), [BigPharmaNews.com](#), 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Mary Villareal](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca